Axogen, Inc.
13631 Progress Boulevard
Suite 400
Alachua
Florida
32615
United States
Tel: 888-296-4361
Fax: 386-462-6801
Website: http://www.axogeninc.com/
237 articles about Axogen, Inc.
-
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
4/16/2024
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens.
-
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
3/5/2024
Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.
-
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
2/13/2024
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2023 fourth quarter and full-year financial results on Tuesday, March 5, 2024, before the market opens.
-
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - February 02, 2024
2/2/2024
Axogen, Inc. announced making Inducement Grants Under NASDAQ Listing Rule 5635 in connection with the employment and appointment of John Manning to the position of Area Vice President of Sales.
-
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
1/18/2024
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with Axoguard Nerve Cap.
-
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
1/4/2024
Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced preliminary unaudited fourth quarter and full-year 2023 revenue.
-
Axogen Announces Promotions on Research and Development TeamCompany Also Announces Departure of Angelo Scopelianos, Ph.D.
1/4/2024
Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced the promotions of three research and development team members.
-
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
1/4/2024
Axogen, Inc. announced that President and Chief Executive Officer Karen Zaderej plans to retire from the Company by January 2025.
-
Axogen, Inc. Appoints Kathy Weiler to its Board of DirectorsWeiler brings 20+ years of strategic and commercial leadership experience to the Axogen, Inc. Board of Directors
12/26/2023
Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023.
-
Axogen Announces Transition of Finance Team Leadership
12/6/2023
Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced the appointment of Mr. Nir Naor as Chief Financial Officer, effective immediately.
-
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 01, 2023
12/1/2023
Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making Inducement Grants Under NASDAQ Listing Rule 5635 in connection with the employment and appointment of Harold D. Tamayo as Vice President of Finance and Investor Relations.
-
Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference
11/20/2023
Axogen, Inc. today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will present at the Piper Sandler 35th Annual Healthcare Conference in New York, NY, on Thursday, November 30, 2023, at 8:50 a.m. E.T.
-
Axogen, Inc. Reports 2023 Third Quarter Financial Results
11/7/2023
Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, reported financial results and business highlights for the third quarter ended September 30, 2023.
-
Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023
10/18/2023
Axogen, Inc. today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023 before the market opens.
-
Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™
9/5/2023
Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced the full launch of Axoguard HA+ Nerve Protector.
-
Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio
8/21/2023
Axogen, Inc. today announced the successful first week of processing for Avance Nerve Graft at the newly opened Axogen Processing Center (APC), in Dayton, Ohio.
-
Axogen, Inc. Reports 2023 Second Quarter Financial Results
8/7/2023
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2023.
-
Axogen to Participate at Canaccord Genuity’s 43rd Annual Growth Conference
7/27/2023
Axogen, Inc. today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will participate in a fireside chat at Canaccord Genuity’s 43rd Annual Growth Conference in Boston, MA, on Wednesday, August 9, 2023, at 2 p.m. ET.
-
Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023
7/26/2023
Axogen, Inc. today announced that it will report second quarter 2023 financial results on Monday, August 7, 2023 after the market closes.
-
Axogen to Participate at JMP Securities Life Sciences Conference
5/12/2023
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Peter Mariani, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference in New York on Monday, May 15, 2023 at 3:00 p.m. ET.